PIN10 A COST CONSEQUENCE ON CONCOMITANT DRUG USE DURING HCV THERAPY IN MANAGED CARE PATIENTS IN THE UNITED STATES  by Le, TK & Yu, H
748 Abstracts
(30–90%) to all oral antibiotics. CONCLUSIONS: TMP-
SMX should no longer be recommended for empiric 
treatment of this disease and should be replaced by nitro-
furantoin. The decrease in resistance to amoxycillin +
clavulanic acid observed for E. coli shows that interven-
tions designed to improve antibiotic prescribing may play
a valuable role in the global effort to combat antibiotic
resistance. Furthermore, the data presented illustrates
that longitudinal surveillance of antibiotic resistance
should be an integral component in the formulation of
antibacterial pharmacopolicy.
INFECTION—Cost Studies
PIN8
PROSPECTIVE STUDY ON ACUTE LOWER
RESPIRATORY TRACT INFECTIONS IN 
GERMAN CHILDREN YOUNGER THAN 3 YEARS
(PRI.DE)—ECONOMIC IMPACT OF
HOSPITALIZED CASES
Ehlken B1, Berger K1, Ihorst G2, Petersen G3, Forster J4
1MERG—Medical Economics Research Group, Munich,
Germany; 2Institute of Medical Statistics, University Freiburg,
Freiburg, Germany; 3Wyeth, Münster, Germany; 4St.
Josefskrankenhaus and University Children’s Hospital Freiburg,
Freiburg, Germany
OBJECTIVES: To calculate the average cost per hospi-
talized patient (case) with lower respiratory tract infec-
tion (LRTI) and to estimate the economic impact of LRTI
due to RSV, parainﬂuenza and inﬂuenza viruses in
Germany. Costs were evaluated from the perspectives of
third party payer, parents and society. METHODS: This
economic analysis is part of the PRI.DE study, which is a
prospective, multicenter, population-based epidemiologi-
cal study. It was carried out over 2 years (1999–2001) on
the impact of LRTI in children aged 0 to 36 months in
Germany. Inclusion of children with pneumonia, bron-
chitis, bronchiolitis, croup and apnea. Nasopharyngeal
secretions were tested for RSV, parainﬂuenza-(PIV), and
inﬂuenza viruses (IV) by Hexaplex PCR (Prodesse, USA).
Medical services consumed were generated by chart ion.
Data regarding parental expenses were collected via tele-
phone interviews within 4 weeks after hospitalization by
using standardized questionnaires. RESULTS: A total of
1035 evaluable cases with community-acquired infections
treated as inpatients enrolled in 6 hospitals were analysed.
Total costs per hospitalized community-acquired LRTI
case amount to €2579 (SD 1874). Main cost driver is
direct medical cost (91%). Mean hospital length of stay
is 7.4 days (SD 6.5). For children under 1 year (n = 596),
total costs amount to €2827 (SD 2213), whereas the costs
for older children (1 to 3 years; n = 439) are lower
(€2242; SD 1132). Total cost of LRTI caused by RSV (n
= 350) is €2772 (SD 1603), caused by PIV (n = 74) €2374
(SD 1644) and by IV (n = 35) €2596 (SD 1214). Treat-
ment of LRTI caused by other pathogens costs on average
€2482 (SD 2131). Annual total expenditures due to hos-
pitalized cases of community-acquired LRTI amount to
€158 million. CONCLUSIONS: LRTI in children up to
the age of three years cause a considerable economic
burden to the health care system in Germany.
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OBJECTIVE: Until 2001 serotype prevalence of
meningococcal disease in Portugal was unknown. Fol-
lowing the ﬁrst release of data it was found that a high
prevalence of type C disease existed in Portugal (>50%
all serotypes). Several conjugated vaccines are currently
available, all having several possible vaccination schemes.
This study estimates the cost-effectiveness of two differ-
ent vaccination schemes using the vaccine MeningiteC®.
METHODS: Using an Excel-based model we estimated
the impact of vaccinating 100,000 children, using alter-
natively 2 different vaccination schemes (1 vs 3 doses).
Disease prevalence was assumed as the one found during
the year previous to the introduction of the vaccine. The
vaccine was assumed as having a 92% efﬁcacy for 5 years,
with no herd immunity. Costs were obtained from ofﬁ-
cial sources, when available. The estimation of resources
for disease and sequelae treatment was obtained by con-
sulting several clinical experts. Costs were determined in
2002 Euros and a discount rate of 5% was used, as
required by Portuguese guidelines. RESULTS: For each
100.000 children vaccinated, using a 3-dose scheme will
result in 345,36 Life-Years Gained (LYG), with cost-
effectiveness ratios of €29.575/LYG—societal, and
€11.272/LYG—3rd payer, while the vaccination with
only one dose will result in 297,58 LYG, with ratios of
€10.806/LYG and €3.768/LYG, respectively. The results
found are sensitive to vaccine price, epidemiology of
disease and mortality rates. Resources consumed due to
disease and sequelae did not inﬂuence ﬁnal results 
considerably. CONCLUSION: Use of meningococcal C
vaccine in Portugal is expected to be cost-effective pro-
vided that no substantial change in the prevalence of the
disease occurs. Decision to use 1 or 3 doses will depend
on both society’s and parent’s willingness to pay since
incremental cost-effectiveness ratios for the 3 vs 1 dose
scheme are considerably high.
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OBJECTIVE: The purpose of this study was to examine
concomitant medications use and associated costs in
hepatitis-C (HCV) patients before and after HCV treat-
ment in a large managed care population. METHODS:
Continuously beneﬁt-eligible patients were identiﬁed
from a managed care database of integrated medical 
and pharmacy claims (~10 million lives). A total of 1812
patients with a new HCV diagnosis between June 1, 2001
and December 31, 2001, who had no HCV-related
medical and prescription claims in a 12-month pre-
diagnosis period and had up to 12 months of medical
follow-up were included in the study. Concomitant med-
ications included all drugs prescribed for treatment of
anemia, neutropenia, depression, and sleeping disorders
that were dispensed between the ﬁrst and last HCV pre-
scription ﬁll date. RESULTS: The study subject median
age was 46 years and 62% were male. The HCV treat-
ment rate was 17% (314 treated vs 1498 untreated) with
a mean of 2.6 months of elapsed time between HCV diag-
nosis and initial HCV prescription claim. Concomitant
medication use was lower in the pre-diagnosis period than
in the follow-up period for anemia agents (3% vs. 9%, p
= 0.004), neutropenia agents (1% vs. 3%, p = 0.05), anti-
depressants (18% vs. 31%, p < 0.0001), non-barbiturate
sedatives (8% vs. 21%, p < 0.0001), and overall con-
comitant use (23% vs. 45%, p < 0.0001). Consequently,
mean cost associated with concomitant drug use was
higher during the HCV therapy as compared to the pre-
diagnosis period ($761 vs. $457, p < 0.0001). CON-
CLUSIONS: In this sample of HCV treated patients, 45%
were prescribed concomitant medications for treatment
of HCV-related conditions during the follow-up period
compared to only 23% in the pre-diagnosis period. This
pattern suggests a cost consequence on concomitant drug
use during HCV therapy. More research is needed to
better understand the association between these con-
comitant agents and cost implications of HCV treatment
in this patient population.
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OBJECTIVES: Abacavir causes hypersensitivity reactions
(HSRs) in about 4% of HIV patients. HSRs can be
serious, result in hospitalisations and incur signiﬁcant
Health care expense. Recent evidence suggests that the
presence of HLA-B57 increases the likelihood of occur-
rence of HSRs. The aim of this analysis is to model the
cost-effectiveness of genotyping, which costs £30 per
patient, as a therapeutic strategy to avoid abacavir—
induced hypersensitivity reactions. METHODS: As HSRs
occur within the ﬁrst few weeks of therapy, a 6-month
time horizon was chosen for the analysis that adopted a
UK National Health Service perspective. Data relating to
time of onset and prevalence of HSRs were obtained from
published sources. An analysis of test characteristics (sen-
sitivity and speciﬁcity) was performed by pooling data
from two previously published studies with data of our
own. The use of Health care resources, and associated
costs of treating HSRs were collected from the records of
16 patients. The cost and selection of substitutes for aba-
cavir (alternative HAART regimens), in the case of posi-
tive testing or occurrence of HSR, were considered in the
analysis but assumed to be equally efﬁcacious. A proba-
bilistic decision analytic model (comparing testing versus
no testing) was formulated and Monte Carlo simulations
performed. RESULTS: When abacavir is used as salvage
therapy, genotyping is cost saving. When used in treat-
ment naïve patients or for regimen simpliﬁcation, the
ICER of genotyping versus conventional “blind” therapy
ranged from being cost saving to £4000 per HSR avoided,
depending on the cost of alternative regimen: the more
expensive the alternative, the less cost effective the test 
is. CONCLUSIONS: Pharmacogenetic testing to prevent
abacavir—induced HSRs appears to be a cost effective use
of Health care resources. A recommendation of routine
adoption of testing for patients eligible for abacavir
therapy may be appropriate.
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OBJECTIVE: To estimate the cost-effectiveness of pegin-
terferon alfa-2a 180mcg/week and ribavirin 1000mg/d
(PegINF + R) relative to interferon alfa-2b 3mln units
thrice weekly and ribavirin 1000mg/d (INF + R) in
chronic hepatitis C patients without preexisting cirrhosis.
METHODS: A Markov model was developed to project
lifelong clinical and economic outcomes in 45-year-old
patients based on published in literature transition prob-
abilities and utility values and Polish data on health care
resource utilisation and unit cost. The duration of treat-
ment was 48 weeks and 24 weeks respectively in patients
with HCVgenotype-1 (group I) and non-1 (group II). Pre-
dictability test was performed after 12 weeks and 24
weeks in those receiving PegINF + R and INF + R respec-
tively. Effectiveness was expressed in LY and QALY. Only
direct medical costs were analysed from Health care
payer’s perspective. The cost-effectiveness threshold was
calculated on the basis of 1-year haemodialysis treatment
cost (60,000 PLN, €1 = 4 PLN; in 2003). Sensitivity
analyses were performed to test the robustness of the
model. RESULTS: PegINF + R relative to INF + R
increased life expectancy by 0.78 LY or 0.46 QALY in
group I and 1.17 LY or 0.78 QALY in group II. The
cost/patient treated with PegINF + R or INF + R was
